To observe the clinical efficacy and safety of alirocumab injection combined with ticagrelor tablets in treating patients with moderate coronary artery stenosis accompanied by angina pectoris.

Patients exhibiting moderate coronary artery stenosis and angina pectoris were categorized into two groups according to their treatment methods: treatment group and control group. Both groups received basic treatment. The control group received additional ticagrelor tablets, starting with a dose of 180 mg, followed by 90 mg twice daily. The treatment group added alirocumab injection at an initial dose of 75 mg, subcutaneously injected every two weeks, with dose adjustments made from weeks 4-8 based on lipid levels. Both groups continued treatment for 12 weeks. The clinical efficacy, angina attack frequency, use of nitroglycerin tablets, echocardiographic parameters, lipid levels, coagulation and myocardial injury markers, Seattle Angina Questionnaire scores, 6-minute walk distances and safety evaluation were compared between the two groups. Safety was also evaluated.

A total of 92 patients were enrolled in this study, with 45 and 47 patients assigned to the control group and the treatment group, respectively. After treatment, the total effective rates were 75.56% (34 cases/45 cases) for the control group and 91.49% (43 cases/47 cases) for the treatment group. The corrected QTc intervals were (387.38±18.62) and (379.29±17.54) ms, respectively; QRS durations were (98.38±7.27) and (97.45±6.74) ms; cardiac outputs were (4.82±0.63) and (5.17±0.68) L·min^-1; cardiac indexes were (3.17±0.42) and (3.39±0.48) L·(min·m²)^-1; total cholesterol levels were (4.11±0.82) and (3.58±0.71) mmol·L^-1; triglyceride levels were (3.42±0.63) and (3.05±0.57) mmol·L^-1; low-density lipoprotein cholesterol levels were (3.42±0.54) and (2.95±0.40) mmol·L^-1; free fatty acid levels were (0.54±0.07) and (0.48±0.08) mmol·L^-1. The differences in the above indicators between the treatment group and the control group were all statistically significant (all P<0.05). The incidence rates of adverse reactions in control group and treatment group were 11.11% (5 cases/45 cases) and 14.89% (7 cases/47 cases), with no statistically significant difference (P>0.05).

Both alirocumab injection combined with ticagrelor tablets and ticagrelor tablets alone can treat moderate coronary artery stenosis associated with angina pectoris, however, the combination therapy more significantly improves efficacy, reduces the frequency of angina attacks and blood lipid levels, enhances overall cardiac function and quality of life, with good safety.